All In Biotech

Drug Trial Radar · NCT05850520

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 892 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

892

Actual

Start

May 15, 2023

Primary completion

Nov 7, 2024

Study completion May 27, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
May 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked. The retina is the very back part of the eye. The blocked vein causes fluid and blood to leak into the retina and thereby causes a swelling of the macula (the center of the retina responsible for fine vision). This swelling is called macular edema. When a vein in the retina is blocked, the levels of a protein called vascular endothelial growth factor (VEGF) rises. VEGF helps the growth of new blood vessels. This can lead to macular edema and may cause the vision to become blurry. The study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease. Standard of care is given every 4 weeks in people with macula edema secondary to RVO. While repeated injections of aflibercept may prevent worsening of vision, it may place a burden on the patient. However, a higher amount (8 mg) compared to the standard of care (2 mg) of IVT aflibercept is being tested in studies. This higher amount could be given less often. The amount of IVT aflibercept given is measured in milligrams, also known as mg. The main purpose of this study is to learn how well a higher amount of the study treatment aflibercept works in people with macular edema secondary to RVO. To answer this, researchers will measure changes in vision called best corrected visual acuity (BCVA) in the study participants between study start and after 36 weeks of treatment. Changes will then be compared between those participants who received the higher amount of IVT aflibercept and those that received standard of care. To learn how safe the study treatment is in the participants, the researchers will count the number of participants from study start and up to 64 weeks later that have: * adverse events * serious adverse events "Adverse events" are any medical problems that the participants have during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think they might be related to the study treatments. An adverse event is considered "serious" when it leads to death, puts the participants' lives at risk, requires hospitalization, causes disability, causes a baby being born with medical problems or is otherwise medically important. Dependent on the treatment group, the participants will either receive the higher amount of aflibercept or standard of care as an intravitreal injection for up to 60 weeks. The study will consist of a test (screening) phase, a treatment phase and an end of study phase. Each participant will be in the study for up to 64 weeks. One visit to the study site is planned during the screening phase, followed by visits approximately every 4 weeks (16 in total) during treatment and one visit at the end of the study. During the study, the study doctors and their team will: * check patients' eye health using various eye examination techniques * measure patients' eye vision (BCVA) * take blood and urine samples * do physical examinations * check vital signs * examine heart health using electrocardiogram (ECG) * do pregnancy tests in women of childbearing age In addition, participants will be asked to fill a questionnaire on vision-related quality of life.

Conditions

  • Macular Edema Secondary to Retinal Vein Occlusion

Interventions

  • Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher doseDrug

    Intravitreally (IVT) injection.

  • Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mgDrug

    Intravitreally (IVT) injection.

  • ShamDrug

    Sham procedure will be given on visits when an active injection is not planned.

  • FluoresceinDiagnostic test

    Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36Time frame: At Week 36

Locations

273 sites in 27 countries. Site status is shown where the registry gives one.

  • Retina Consultants of Orange County - Fullerton

    Fullerton, California

  • South Coast Retina - Long Beach

    Long Beach, California

  • Northern California Retina Vitreous Associates - Mountain View Office

    Mountain View, California

  • Desert Retina Consultants - Palm Springs Office

    Palm Springs, California

  • Azul Vision Pasadena

    Pasadena, California

  • Retina Consultants of Southern California

    Redlands, California

  • Retina Consultants of Southern Colorado, PC

    Colorado Springs, Colorado

  • New England Retina Associates

    New London, Connecticut

  • Rand Eye Institute

    Deerfield Beach, Florida

  • National Ophthalmic Research Institute - Fort Myers

    Fort Myers, Florida

  • The Eye Institute of West Florida - Largo

    Largo, Florida

  • Florida Eye Associates - Melbourne Main Office

    Melbourne, Florida

  • Florida Retina Institute - Orlando

    Orlando, Florida

  • Retina Specialty Institute - Pensacola

    Pensacola, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • Retina Vitreous Associates of Florida - Saint Petersburg

    St. Petersburg, Florida

  • East Florida Eye Institute

    Stuart, Florida

  • Center for Retina and Macular Disease - Winter Haven

    Winter Haven, Florida

  • Marietta Eye Clinic

    Marietta, Georgia

  • Retina Associates - Elmhurst

    Elmhurst, Illinois

  • University Retina and Macula Associates - Oak Forest

    Oak Forest, Illinois

  • Retina Associates - Lenexa

    Lenexa, Kansas

  • The Retina Care Center - Baltimore

    Baltimore, Maryland

  • Cumberland Valley Retina Consultants | Hagerstown, MD

    Hagerstown, Maryland

  • Mid Atlantic Retina Specialists - Hagerstown

    Hagerstown, Maryland

  • Vitreo-Retinal Associates - Worcester

    Grand Rapids, Michigan

  • RCM - St. Louis Park Retina Clinic

    Saint Louis Park, Minnesota

  • Retina Consultants of Nevada - Summerlin

    Las Vegas, Nevada

  • Retina Center of New Jersey

    Bloomfield, New Jersey

  • NJ Retina - New Brunswick

    New Brunswick, New Jersey

  • NJ Retina | Teaneck

    Teaneck, New Jersey

  • Vision Research Center

    Albuquerque, New Mexico

  • Vitreoretinal Consultants of NY - Great Neck

    Great Neck, New York

  • Vitreoretinal Consultants of NY - Hauppauge

    Hauppauge, New York

  • Ophthalmic Consultants of Long Island

    Lynbrook, New York

  • Retina Associates of Western New York

    Rochester, New York

  • Cincinnati Eye Institute - Blue Ash

    Blue Ash, Ohio

  • Midwest Retina - Main Office

    Dublin, Ohio

  • Retina Consultants, LLC

    Salem, Oregon

  • Mid Atlantic Retina - Bethlehem

    Bethlehem, Pennsylvania

Showing 40 of 273 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.